Convergent Therapeutics
Convergent Therapeutics develops radiopharmaceutical therapies for prostate cancer using proprietary technology.
Founded
2021Convergent Therapeutics develops radiopharmaceutical therapies for prostate cancer using proprietary technology.
Convergent Therapeutics, founded with a mission to advance cancer treatment, focuses on developing radiopharmaceutical therapies specifically for prostate cancer. Utilizing proprietary technology licensed from Cornell University and developed by Dr. Neil Bander, the company’s flagship product, CONV 01-α, is a monoclonal antibody conjugated with the radioactive alpha particle emitter 225Ac. This innovative therapy targets the prostate-specific membrane antigen (PSMA), aiming to improve patient outcomes in a market focused on advanced cancer treatments.
Notable figures associated with Convergent Therapeutics include Dr. Neil Bander, a Professor of Urologic Oncology at Weill Cornell Medicine. The company has achieved significant milestones, including FDA clearance of its Investigational New Drug (IND) application for CONV 01-α. This clearance marks a critical step towards clinical trials and potential commercialization. Convergent Therapeutics is poised to make a substantial impact in the field of oncology, offering promising new treatment options for prostate cancer patients.
Companies similar to Convergent Therapeutics include ConverGene, Adcentrx Therapeutics, Artbio and Conjupro Biotherapeutics.
Convergent Therapeutics was founded in 2021.
Convergent Therapeutics' headquarters is located in Cambridge, MA, US.
Convergent Therapeutics' most recent funding round was for $90M (USD) in May 2023.
As of May 3, 2023, Convergent Therapeutics has disclosed funding of $90M (USD). Undisclosed round amounts are excluded.
Convergent Therapeutics has 6 employees as of Feb 5, 2024.
Conjupro Biotherapeutics
